Current Report · Items 1.01, 9.01 · 8-K
FOXO TECHNOLOGIES INC
Entry into a Material Definitive Agreement
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description of Exhibit ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── 2.1 Asset Purchase Agreement, dated July 22, 2026, by and between Vector BioSource, Inc.…
Filed Jul 27, 2026Accepted Jul 27, 2026, 4:05 PM EDTCIK 1812360Accession 0001493152-26-034793
Company context
We are a healthcare services and technology company operating in three reportable business segments: (i) Healthcare, (ii) Life Science Services and (iii) Labs, formerly referred to as Labs and Life. These segments further operate in four synergistic divisions, a rural hospital division and a mental and behavioral health division, which make up our Healthcare segment, a biospecimens division, which makes up our Life Science Services segment and an epigenetics diagnostics and interpretation division, which makes up our Labs segment. Our rural hospital division, biospecimens division and epigenetics diagnostics and interpretation division operate through wholly owned subsidiaries, and our behavioral health division operates through a majority-owned subsidiary.
Current securities
Historical securities (10)
DWINNYSE · EQUITY · Historical · closed Sep 15, 2022DWIN.UNNYSE · UNIT · Historical · closed Sep 15, 2022DWIN.WSNYSE · WARRANT · Historical · closed Sep 15, 2022FOXONYSE_AMERICAN · EQUITY · Historical · closed Aug 12, 2025FOXOOTC · EQUITY · Historical · closed Jul 1, 2026FOXOOTC · EQUITY · Historical · closed Oct 19, 2026FOXODOTC · EQUITY · Historical · closed Jul 30, 2026FOXOWOTC · WARRANT · Historical · closed May 17, 2023FOXOWOTC · WARRANT · Historical · closed Oct 19, 2026FOXO.WSNYSE · WARRANT · Historical · closed Jan 24, 2023 Disclosure sections
Items 1.01, 9.01Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 9.01Item 9.01 - Financial Statements and Exhibits
Item 9.01
Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit Number Description
of Exhibit
────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
2.1 Asset Purchase Agreement, dated July 22, 2026, by and between Vector BioSource, Inc. and Grifols Bio Supplies, Inc.*
104 Cover
Page Interactive Data File (formatted in Inline XBRL)
*Certain
schedules and exhibits omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of any
omitted schedule or exhibit to the SEC upon request.
